---
id: meningitis-empiric-treatment_083
category: clinical_syndromes
tags: [meningitis, empiric-treatment, LP-before-CT, dexamethasone, bacterial-meningitis]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Acute Bacterial Meningitis: Empiric Treatment

**Q:** What is the approach to empiric treatment of suspected acute bacterial meningitis, including when to perform LP vs. CT first, dexamethasone timing, and age-based empiric antibiotic regimens?

**A:**

## CLINICAL PRESENTATION

**Classic Triad (Only 44% Have All Three):**
- **Fever**
- **Neck stiffness (nuchal rigidity)**
- **Altered mental status**

**Other Features:**
- **Headache** (87%)
- **Photophobia**
- **Nausea/vomiting**
- **Seizures** (20-30%)
- **Focal neurologic deficits** (10-20%)

**Key Point:** **Absence of all 4 findings (fever, headache, neck stiffness, altered mental status) = <0.5% have meningitis** (high negative predictive value)

---

## DIAGNOSTIC APPROACH

---

### **Step 1: Suspect Meningitis**

**When to Suspect:**
- **Fever + headache + neck stiffness**
- **Fever + altered mental status**
- **Fever + seizure** (new-onset)
- **Petechial/purpuric rash** (Neisseria meningitidis)

---

### **Step 2: Blood Cultures + Empiric Antibiotics + Dexamethasone (BEFORE LP/CT)**

**CRITICAL:** **Do NOT delay antibiotics** waiting for LP or CT

**Order:**
1. **Blood cultures** (≥2 sets)
2. **Empiric antibiotics** (see below - based on age/risk factors)
3. **Dexamethasone** 10 mg IV (if bacterial meningitis suspected)

**Then proceed to LP** (unless contraindications - see below)

**Key Point:** **"Blood cultures → Antibiotics + Dexamethasone → LP"** (Do NOT delay antibiotics)

---

### **Step 3: Lumbar Puncture (LP) vs. Head CT First**

**Perform LP Immediately (Without Head CT) If:**
- **No features suggesting ↑ ICP or mass lesion:**
  - NO focal neurologic deficits
  - NO new-onset seizure (<1 week)
  - NO papilledema
  - NO immunocompromise (HIV, transplant)
  - NO altered consciousness (GCS ≥15)

**Perform Head CT BEFORE LP If:**
- **↑ Intracranial pressure (ICP) or mass lesion suspected:**
  - **Focal neurologic deficits** (hemiparesis, aphasia, visual field defect)
  - **New-onset seizure** (<1 week)
  - **Papilledema** (on fundoscopy)
  - **Immunocompromise** (HIV CD4 <200, transplant) - risk of toxoplasmosis, abscess
  - **Altered consciousness** (GCS <15)
  - **Moderate-severe impaired consciousness** (GCS <11)

**Key Point:** **~50% of patients require CT before LP** (based on these criteria)

---

**CT Findings:**
- **If CT shows mass lesion, abscess, or significant midline shift:** **DO NOT perform LP** (risk of herniation)
- **If CT negative:** **Proceed with LP**

**Key Point:** **Even if CT required, give antibiotics + dexamethasone FIRST** (do NOT delay)

---

### **Step 4: Lumbar Puncture**

**CSF Studies:**
- **Cell count with differential**
- **Glucose, protein**
- **Gram stain, bacterial culture**
- **Opening pressure** (if no contraindication)
- **Consider:** HSV PCR, enterovirus PCR, cryptococcal antigen, VDRL, AFB smear/culture, viral culture

**Typical Findings (Bacterial Meningitis):**

| **Parameter** | **Normal** | **Bacterial Meningitis** | **Viral Meningitis** | **Tuberculous Meningitis** |
|---------------|------------|--------------------------|----------------------|----------------------------|
| **WBC** | <5 cells/μL | **>1,000** (often >10,000) | 10-1,000 (usually <500) | 50-500 |
| **Differential** | N/A | **Neutrophil predominance** (>80%) | Lymphocyte predominance | Lymphocyte predominance |
| **Glucose** | 45-80 mg/dL (CSF:serum >0.6) | **<40 mg/dL** (CSF:serum <0.4) | Normal | Low (<45 mg/dL) |
| **Protein** | 15-45 mg/dL | **>200 mg/dL** (often >500) | 50-100 mg/dL | 100-500 mg/dL |
| **Gram stain** | Negative | **Positive 60-90%** | Negative | Negative (AFB <20%) |

**Key Point:** **Bacterial meningitis = ↑↑ WBC (>1,000, PMN predominance), ↓ glucose (<40), ↑↑ protein (>200)**

---

## EMPIRIC ANTIBIOTIC THERAPY

**Key Principle:** **Empiric therapy covers most likely pathogens by age and risk factors**

---

### **1. Neonates (<1 Month)**

**Common Pathogens:**
- **Group B Streptococcus** (S. agalactiae) - #1
- ***Escherichia coli*** (and other Gram-negatives)
- ***Listeria monocytogenes***
- **Less common:** S. aureus, Enterococcus

**Empiric Regimen:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Ampicillin** | 300-400 mg/kg/day IV divided q6h (max 12g/day) |
| **PLUS** | |
| **Gentamicin** | 5-7.5 mg/kg IV q24h OR divided q8h |
| **OR** | |
| **Cefotaxime** (alternative to gentamicin) | 200-300 mg/kg/day IV divided q6-8h |

**Key Point:** **Ampicillin ESSENTIAL** (covers Listeria, which cephalosporins do NOT cover)

---

### **2. Infants & Children (1 Month - 50 Years)**

**Common Pathogens:**
- ***Streptococcus pneumoniae*** (pneumococcus) - #1
- ***Neisseria meningitidis*** (meningococcus)
- ***Haemophilus influenzae*** type b (Hib) - rare since vaccination

**Empiric Regimen:**

| **Agent** | **Dosing (Adult)** | **Dosing (Pediatric)** |
|-----------|---------------------|------------------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h (target trough 15-20 μg/mL) | 15-20 mg/kg IV q6-8h |
| **PLUS** | | |
| **Ceftriaxone** | 2g IV q12h | 100 mg/kg/day IV divided q12-24h (max 4g/day) |
| **OR** | | |
| **Cefotaxime** | 2g IV q4-6h | 200-300 mg/kg/day IV divided q6-8h (max 12g/day) |

**Rationale:**
- **Vancomycin:** Covers **penicillin-resistant S. pneumoniae** (PRSP)
- **Ceftriaxone/cefotaxime:** Covers S. pneumoniae, N. meningitidis, H. influenzae

**Key Point:** **Vancomycin + ceftriaxone = standard for age 1 month - 50 years**

---

### **3. Adults >50 Years**

**Common Pathogens:**
- ***Streptococcus pneumoniae*** - #1
- ***Listeria monocytogenes*** (↑ risk >50 years)
- ***Neisseria meningitidis***
- **Gram-negative bacilli** (E. coli, Klebsiella)

**Empiric Regimen:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h (target trough 15-20 μg/mL) |
| **PLUS** | |
| **Ceftriaxone** | 2g IV q12h |
| **PLUS** | |
| **Ampicillin** | 2g IV q4h |

**Rationale:**
- **Ampicillin added** to cover ***Listeria monocytogenes*** (cephalosporins do NOT cover Listeria)

**Key Point:** **Age >50 years = add ampicillin** (for Listeria coverage)

---

### **4. Immunocompromised Patients**

**Additional Pathogens:**
- ***Listeria monocytogenes***
- **Gram-negative bacilli** (E. coli, Klebsiella, Pseudomonas)
- **Fungi** (Cryptococcus neoformans - HIV)
- ***Mycobacterium tuberculosis***

**Empiric Regimen:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h |
| **PLUS** | |
| **Cefepime** OR **Meropenem** | 2g IV q8h OR 2g IV q8h |
| **PLUS** | |
| **Ampicillin** | 2g IV q4h |

**Rationale:**
- **Cefepime or meropenem:** Broader Gram-negative coverage (including *Pseudomonas*)
- **Ampicillin:** Listeria coverage

**If HIV with CD4 <100:**
- Consider **cryptococcal meningitis** → Add **amphotericin B** + **flucytosine** (if CSF India ink positive or cryptococcal antigen positive)

---

### **5. Post-Neurosurgery or CSF Shunt**

**Common Pathogens:**
- **Coagulase-negative Staphylococci** (CoNS - S. epidermidis)
- ***Staphylococcus aureus*** (MRSA)
- **Gram-negative bacilli** (including *Pseudomonas aeruginosa*, *Acinetobacter*)
- ***Propionibacterium acnes*** (now *Cutibacterium acnes*)

**Empiric Regimen:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h (target trough 15-20 μg/mL) |
| **PLUS** | |
| **Cefepime** OR **Ceftazidime** OR **Meropenem** | 2g IV q8h |

**Rationale:**
- **Vancomycin:** MRSA, CoNS
- **Cefepime/ceftazidime/meropenem:** Pseudomonas, Gram-negatives

**If CSF shunt infection:** **Shunt removal usually required** (antibiotics alone insufficient)

---

### **6. Penetrating Head Trauma**

**Common Pathogens:**
- ***Staphylococcus aureus***
- **Gram-negative bacilli** (including *Pseudomonas*)
- **Clostridium species** (if soil contamination)

**Empiric Regimen:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h |
| **PLUS** | |
| **Cefepime** OR **Meropenem** | 2g IV q8h |
| **PLUS (if soil contamination)** | |
| **Metronidazole** | 500 mg IV q8h |

---

## ADJUNCTIVE DEXAMETHASONE

---

**Indication:**
- **Suspected or confirmed bacterial meningitis** (especially S. pneumoniae)

**Dosing:**
- **Dexamethasone** 10 mg IV q6h x **4 days**

**Timing:**
- **Give BEFORE or WITH first antibiotic dose**
- **Benefit lost if given >1 hour after antibiotics**

**Key Point:** **Dexamethasone MUST be given before/with antibiotics** (not after)

---

**Efficacy:**
- **Reduces mortality** in S. pneumoniae meningitis (RR 0.5)
- **Reduces neurologic sequelae** (hearing loss, cognitive impairment)
- **No benefit** in H. influenzae, N. meningitidis (but no harm)

**When to STOP Dexamethasone:**
- If **NOT bacterial meningitis** (viral, fungal, TB) → Discontinue
- If **Gram stain or culture negative** at 48h → Consider stopping

---

## DURATION OF THERAPY

| **Organism** | **Duration** |
|--------------|--------------|
| ***Neisseria meningitidis*** | **5-7 days** |
| ***Haemophilus influenzae*** | **7 days** |
| ***Streptococcus pneumoniae*** | **10-14 days** |
| ***Listeria monocytogenes*** | **≥21 days** |
| **Gram-negative bacilli** | **21 days** |
| **Group B Streptococcus** | **14-21 days** |

---

## CHEMOPROPHYLAXIS FOR CONTACTS

---

### ***Neisseria meningitidis* (Meningococcus):**

**Indication:**
- **Close contacts** (household, daycare, anyone with direct contact with oral secretions)

**Regimen:**
- **Rifampin** 600 mg PO BID x 2 days (4 doses)
- **OR Ciprofloxacin** 500 mg PO x 1 dose
- **OR Ceftriaxone** 250 mg IM x 1 dose

**Key Point:** **Give prophylaxis ASAP** (within 24h)

---

### ***Haemophilus influenzae* Type B (Hib):**

**Indication:**
- **Household contacts** with unvaccinated children <4 years

**Regimen:**
- **Rifampin** 600 mg PO daily x 4 days

---

### ***Streptococcus pneumoniae*:**
- **NO chemoprophylaxis indicated**

---

## SPECIAL CONSIDERATIONS

---

### **Penetrating CSF Leak (Basilar Skull Fracture, Post-Op):**

**Do NOT give prophylactic antibiotics**
- No clear benefit
- ↑ Risk of resistant organisms

---

### **Pregnancy:**

**Listeria coverage ESSENTIAL:**
- **Ampicillin** + **ceftriaxone** + **vancomycin**

---

**Mnemonic: "Don't DELAY - Blood, Antibiotics, Dex, LP"**
- **D**on't delay antibiotics
- **B**lood cultures first
- **A**ntibiotics + **D**examethasone (before LP)
- **L**P after (or CT if contraindications)

**Mnemonic: "VAN + CEF for Young Adults"**
- **VAN**comycin + **CEF**triaxone
- Age 1 month - 50 years

**Mnemonic: "Add AMP After 50 (Listeria)"**
- **A**dd **AMP**icillin
- **A**fter age **50**
- **L**isteria coverage

**Mnemonic: "Dex BEFORE Antibiotics (Not After)"**
- **D**examethasone
- **BEFORE** (or with) first antibiotic dose
- Benefit lost if >1h after

**Clinical Pearls:**
- **Do NOT delay antibiotics** waiting for LP or CT (give blood cultures → antibiotics → then LP)
- **Dexamethasone 10 mg IV BEFORE/WITH first antibiotic dose** (benefit lost if >1h after)
- **CT before LP if:** Focal deficits, seizure, papilledema, immunocompromise, altered consciousness
- **~50% of patients** meet criteria for CT before LP
- **Vancomycin + ceftriaxone = standard** for age 1 month - 50 years
- **Add ampicillin for age >50 years** (Listeria coverage)
- **Cephalosporins do NOT cover Listeria** (ampicillin required)
- **Neonates:** Ampicillin + gentamicin (or cefotaxime)
- **Post-neurosurgery:** Vancomycin + cefepime/meropenem (Pseudomonas, MRSA, CoNS)
- **Immunocompromised:** Vancomycin + cefepime/meropenem + ampicillin
- **Bacterial meningitis CSF:** WBC >1,000 (PMN), glucose <40, protein >200, Gram stain positive 60-90%
- **Duration:** N. meningitidis 5-7d, S. pneumoniae 10-14d, Listeria ≥21d
- **Chemoprophylaxis:** Rifampin/ciprofloxacin for meningococcus contacts (NOT pneumococcus)

**Media:** None

**Sources:** [IDSA 2004 - Bacterial Meningitis Guidelines], [Lancet 2021 - Acute bacterial meningitis], [NEJM 2024 - Meningitis management update], [European Society of Clinical Microbiology 2023 - Dexamethasone in meningitis], [CDC 2024 - Meningococcal disease prophylaxis]
